{site_meta && site_meta.display_name} Logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

Cyber Stocks Tumble Amid Reports Anthropic is Testing New AI Model

March 31, 2026Cybersecurity shares fell sharply on March 27 after reports surfaced that Anthropic is testing a new AI system with advanced cyber capabilities and possible security concerns. The way news of Anthropic’s model is spooking investors in cybersecurity firms and other industries shows the disruptive potential of AI and underscores why early movers like Core AI Holdings Inc.


Larry Fink Reconsiders His Crypto Skepticism as BlackRock’s ETF Soars

March 31, 2026Raising venture capital has become more challenging for cryptocurrency startups as investors pull back and tighten their criteria in a cooling market. Sami Start, CEO and founder of crypto infrastructure firm Transak, says the shift marks a clear departure from the previous boom cycle, when funding flowed more freely across the sector.


Why Crypto Startups Are Struggling to Attract VC Funding

March 31, 2026Raising venture capital has become more challenging for cryptocurrency startups as investors pull back and tighten their criteria in a cooling market. Sami Start, CEO and founder of crypto infrastructure firm Transak, says the shift marks a clear departure from the previous boom cycle, when funding flowed more freely across the sector.


InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication

March 31, 2026Annovis Bio (NYSE: ANVS) announced the publication of an article in The Scientist detailing the discovery and development of its lead drug candidate buntanetap, as the company advances ongoing Phase 3 and extension studies in Alzheimer’s disease and Parkinson’s disease. The company said the article provides historical and scientific context for buntanetap’s progression, with current trials showing approximately 70% enrollment in early Alzheimer’s and 20% enrollment in Parkinson’s, underscoring its focus on advancing neurodegenerative therapies toward key clinical and regulatory milestones.


InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Phase 1 Data for Lyme Disease Candidate TNX-4800, Plans Phase 2 Study

March 31, 2026Tonix Pharmaceuticals (NASDAQ: TNXP) announced positive Phase 1 data for TNX-4800, a long-acting monoclonal antibody targeting Borrelia burgdorferi, demonstrating rapid absorption, sustained protective levels for at least four months and a favorable safety profile in healthy subjects. The company said the single-dose subcutaneous therapy could offer a preventative option for Lyme disease, with plans to initiate an adaptive Phase 2 field study in the first half of 2027, pending FDA clearance, to evaluate protection in individuals in endemic areas.


BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

March 31, 2026Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for dusquetide in Behçet’s Disease, ongoing development of SGX302 and SGX945 programs and a year-end cash position of approximately $7.


BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Selects Global Brand Name Candidate for AVERSA(TM) Fentanyl Patch

March 31, 2026Nutriband (NASDAQ: NTRB) announced it has selected a proposed worldwide brand name for its abuse-deterrent fentanyl transdermal system, with plans to submit the name and product labeling to the FDA and international regulators as well as file for trademark protection. The company said the product, developed using its AVERSA(TM) technology, could become the first abuse-deterrent fentanyl patch designed to reduce misuse and accidental exposure, targeting a potential peak annual U.


BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline With Multiple 2026 Milestones in View

March 31, 2026Lantern Pharma (NASDAQ: LTRN) reported fourth-quarter and full-year 2025 operational highlights led by continued progress in its LP-300 Phase 2 HARMONIC trial, completion of targeted enrollment in Japan, planned protocol discussions with the FDA in mid-May 2026 and advancement of LP-184, LP-284 and STAR-001 across multiple oncology indications. The company said its AI-driven portfolio now targets an estimated annual market opportunity of more than $15 billion, while its RADR(R) platform and newly introduced withZeta.


Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

March 31, 2026 Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that the company’s solutions are designed to address. Cardio Diagnostics has developed a proprietary platform that integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample.


420 with CNW — Feds Arrest Four During Operations Targeting Illicit Marijuana in Las Vegas

March 30, 2026Federal prosecutors have charged four individuals accused of operating multiple illegal cannabis cultivation sites across the Las Vegas Valley, according to information obtained by the 8 News Now Investigators. These arrests highlight the lengths to which black market marijuana operators will go to sustain their operations and make it harder for licensed companies like Curaleaf Holdings Inc.


MissionIRNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Appoints Veloce Executives To Drive Growth Strategy

March 30, 2026SEGG Media (NASDAQ: SEGG, LTRYW) announced the appointments of Daniel Bailey as chief commercial officer and Jack Clarke as chief strategy officer following its Veloce acquisition, as the company advances a 90-day plan focused on integration, execution, and monetization. The new executives bring experience scaling Veloce Media Group and driving global partnerships and revenue growth, with SEGG Media targeting near-term expansion through its digital assets, including Sports.